Mainz Biomed Expands into Switzerland with labor team w  Partnership to Launch DNA-Based Colorectal Cancer Screening Test BERKELEY, US – MAINZ, Germany – February 20, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a  [ … ]

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness MonthUpdated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany BERKELEY, US and MAINZ, Germany – February 11, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genet [ … ]

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements BERKELEY, US – MAINZ, Germany – January 27, 2025 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that on January 23, 2025, the Company receive [ … ]

 Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second [ … ]